BRAF and melanoma: Based on these findings, they suggested that treatment of BRAF-mutant melanomas with a combination of a BRAF inhibitor and an AMPK activator (phenformin) could offer therapeutic advantages over BRAF inhibitor (BRAFi) single agent therapy.